News

The Mevopur colorants block UV, thereby helping to protect UV sensitive pharmaceutical products. The pre-evaluated Mevopur colourants help reduce customers’ development times and costs, and minimize risk of

The study will evaluate the oral bioavailability of RX-3117 in humans. The company will continue the enrollment through the first half of 2012 and expects to release the

As per the agreement, the use of pSivida’s technology as a delivery system for a treatment for dry age related macular degeneration (Dry AMD) will be evaluated. pSivida

MN-166 is used for certain neurological conditions, including progressive forms of multiple sclerosis, neuropathic pain, and drug addiction. The patent once received is expected to expire by the

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of 29 October 2012. CRTX 080 is a non-peptide, oral capsule that works by reducing

The partnership will identify important characteristics of diseased fibrotic tissue on which Epistem will apply its proprietary RNA-Amp technology to facilitate building an in depth understanding of the

The new AMPAKINE patents cover a series of compounds including CX2007 and CX2076, which exhibit a long duration of action and pharmacokinetic properties through August 2028. The company

The FDA had visited the Aveva manufacturing facility where ONSOLIS is produced and reported the formation of microscopic crystals and fading of the color during the 24-month shelf

Both the companies have agreed to move forward independently. As of 12 March 2012, all rights licensed to Pfizer will revert to Biocon, and all insulin distributed under